# Pulmonary Hypertension FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/pulmonary-hypertension

> 2 upcoming FDA catalysts in pulmonary Hypertension: WINREVAIR (sotatercept, MRK) on Jan to Apr 2030 (topline data readout); WINREVAIR (sotatercept, MRK) on January 2030 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 30, 2026 | [TNX-103 primary completion](https://sec-api.dev/pdufa/tnx-103) | TENX | Pulmonary Hypertension | completed | "NCT05983250 (LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ACTUAL); Lead Sponsor Tenax Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05983250)) |
| October 9, 2026 | [PF-07868489 primary completion](https://sec-api.dev/pdufa/pf-07868489) | PFE | Pulmonary Hypertension | withdrawn | "NCT07073820 (A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-10-09 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07073820)) |
| Jan to Apr 2030 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Hypertension | scheduled | "NCT07839585 (A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07839585)) |
| January 2030 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Hypertension | scheduled | "NCT07839585 (A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07839585)) |

## Drugs

- [TNX-103](https://sec-api.dev/pdufa/tnx-103) (TENX)
- [PF-07868489](https://sec-api.dev/pdufa/pf-07868489) (PFE)
- [WINREVAIR (sotatercept)](https://sec-api.dev/pdufa/sotatercept) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/pulmonary-hypertension.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pulmonary Hypertension FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/pulmonary-hypertension

```bibtex
@misc{secapidev_indications_pulmonary_hypertension_20261116,
  title        = {Pulmonary Hypertension FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/pulmonary-hypertension}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_pulmonary_hypertension_20261116","title":"Pulmonary Hypertension FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/pulmonary-hypertension","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
